{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:19:48Z","timestamp":1793225988214,"version":"4.5.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Diagnostic biomarkers for immune checkpoint inhibitor pneumonitis (ICIP) are lacking. Bronchoalveolar lavage (BAL) lymphocytosis has been associated with ICIP, but studies have not evaluated BAL lymphocytosis as a diagnostic biomarker for ICIP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Purpose<\/jats:title><jats:p>This study aimed to measure the association of BAL immune cell percentage with ICIP and test its performance as a diagnostic biomarker.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a retrospective chart review of 476 patients treated with ICIs for solid organ or hematologic malignancies who underwent BAL between 2016 and 2022. Two independent reviewers, blinded to the results of BAL cell percentage, confirmed the diagnosis of ICIP or other conditions (e.g., pneumonia) based on clinical history and radiology. We constructed logistic regression models to assess the relationship between BAL lymphocyte, eosinophil, and neutrophil percentages and the diagnosis of pneumonitis, and the area under the receiver-operator curves (AUROC) was used to assess their discriminatory function. We measured the association of BAL immune cell percentages with 1-year overall survival using Cox proportional hazard models adjusted for age and cancer diagnosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Each 1% increase in lymphocyte (OR 1.01, 95% CI 1.01\u20131.02, <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001) and eosinophil percentage (OR 1.05, 95% CI 1.01\u20131.11, <jats:italic>p<\/jats:italic>\u202f=\u202f0.01) were independently associated with pneumonitis, while neutrophil percentage was inversely associated (OR 0.99, 95% CI 0.98\u20130.99, p\u202f=\u202f0.01) with pneumonitis. In multivariable analysis, lymphocyte percentage (OR 1.02, 95% CI 1.009\u20131.04, <jats:italic>p<\/jats:italic>\u202f=\u202f0.002) and eosinophil percentage (OR 1.10, 95% CI 1.01\u20131.23, <jats:italic>p<\/jats:italic>\u202f=\u202f0.05) were both associated with ICIP. The AUROC for BAL lymphocytes to diagnose ICIP was 0.62 (95% CI 0.57\u20130.67, optimal cutoff 15.5%, sensitivity 69%, and specificity 52%) and the AUROC for eosinophils was 0.61 (95% CI 0.56\u20130.66, optimal cutoff 1%, sensitivity 58%, and specificity 62%). In patients with pneumonitis, lymphocyte percentage (HR 0.99, 95% CI 0.97\u20131.00, <jats:italic>p<\/jats:italic>\u202f=\u202f0.02), neutrophil percentage (HR 1.01, 95% CI 1.00\u20131.02, <jats:italic>p<\/jats:italic>\u202f=\u202f0.05), and eosinophil percentage (HR 0.93, 95% CI 0.86\u20130.99, <jats:italic>p<\/jats:italic>\u202f=\u202f0.03) were associated with 1-year survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>BAL lymphocytosis and eosinophilia are associated with ICIP, but their ability to discriminate ICIP from other conditions is modest. BAL immune cell percentages may have prognostic value for 1-year survival, but this likely reflects the morbidity of other pulmonary diseases that require BAL for evaluation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1582714","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T07:00:25Z","timestamp":1748934025000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Bronchoalveolar lavage cell percentages as diagnostic markers of immune checkpoint inhibitor pneumonitis"],"prefix":"10.3389","volume":"12","author":[{"given":"Mahnoor","family":"Mir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Antonio Amezcua","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Del Rio","family":"Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adarsh","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diwakar D.","family":"Balachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Bashoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto F.","family":"Casal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burton F.","family":"Dickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Eapen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott E.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horiana","family":"Grosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Ost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce F.","family":"Sabath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickie R.","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadia A.","family":"Faiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Altan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Sheshadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with Cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e004670","DOI":"10.1136\/jitc-2022-004670","article-title":"Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study","volume":"10","author":"Tiu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1111\/1759-7714.13187","article-title":"High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer","volume":"10","author":"Tone","year":"2019","journal-title":"Thorac Cancer"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.clon.2023.07.003","article-title":"Pneumonitis after concurrent Chemoradiation and immune checkpoint inhibition in patients with locally advanced non-small cell lung Cancer","volume":"35","author":"Altan","year":"2023","journal-title":"Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","article-title":"PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course","volume":"22","author":"Nishino","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1164\/rccm.201202-0320ST","article-title":"American Thoracic Society Committee on, an official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease","volume":"185","author":"Meyer","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1172\/JCI128654","article-title":"The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis","volume":"129","author":"Suresh","year":"2019","journal-title":"J Clin Invest"},{"key":"ref10","year":""},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1016\/j.cllc.2019.10.009","article-title":"Lower survival in patients who develop pneumonitis following immunotherapy for lung Cancer","volume":"21","author":"Suresh","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1164\/ajrccm\/142.3.642","article-title":"Diagnostic significance of increased bronchoalveolar lavage fluid eosinophils","volume":"142","author":"Allen","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1164\/rccm.201804-0650OC","article-title":"Multidimensional assessment of the host response in mechanically ventilated patients with suspected pneumonia","volume":"199","author":"Walter","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1513\/AnnalsATS.202007-818ED","article-title":"Making sense of Bronchoalveolar lavage lymphocytosis in fibrotic interstitial lung disease","volume":"17","author":"Ryerson","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"590494","DOI":"10.3389\/fimmu.2020.590494","article-title":"Distinct Immunophenotypes of T cells in Bronchoalveolar lavage fluid from leukemia patients with immune checkpoint inhibitors-related pulmonary complications","volume":"11","author":"Kim","year":"2021","journal-title":"Front Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e005323","DOI":"10.1136\/jitc-2022-005323","article-title":"Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis","volume":"10","author":"Franken","year":"2022","journal-title":"J Immunother Cancer"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1038\/s41388-023-02805-4","article-title":"Deciphering pathogenic cellular module at single-cell resolution in checkpoint inhibitor-related pneumonitis","volume":"42","author":"Cui","year":"2023","journal-title":"Oncogene"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"100868","DOI":"10.1016\/j.xcrm.2022.100868","article-title":"Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors","volume":"4","author":"Bukhari","year":"2023","journal-title":"Cell Rep Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/S0091-6749(99)70107-7","article-title":"Apoptosis of eosinophils and lymphocytes in allergic inflammation","volume":"104","author":"Ohta","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"827199","DOI":"10.3389\/fonc.2022.827199","article-title":"Eosinophil as a biomarker for diagnosis, prediction, and prognosis evaluation of severe checkpoint inhibitor pneumonitis","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2020.08.015","article-title":"Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors","volume":"150","author":"Chu","year":"2020","journal-title":"Lung Cancer"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1234142","DOI":"10.3389\/fimmu.2023.1234142","article-title":"Neutrophil to lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"19596","DOI":"10.1038\/s41598-024-70214-y","article-title":"Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer","volume":"14","author":"Sugimoto","year":"2024","journal-title":"Sci Rep"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12890-020-1056-7","article-title":"Association between peripheral blood\/bronchoalveolar lavage eosinophilia and significant oxygen requirements in patients with acute eosinophilic pneumonia","volume":"20","author":"Choi","year":"2020","journal-title":"BMC Pulm Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.4049\/jimmunol.156.11.4422","article-title":"Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes","volume":"156","author":"Meagher","year":"1996","journal-title":"J Immunol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1249511","DOI":"10.3389\/fimmu.2023.1249511","article-title":"Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept","volume":"14","author":"Aminu","year":"2023","journal-title":"Front Immunol"}],"updated-by":[{"DOI":"10.3389\/fmed.2025.1646108","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000}}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1582714\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T17:17:10Z","timestamp":1750871830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1582714\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":26,"alternative-id":["10.3389\/fmed.2025.1582714"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1582714","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fmed.2025.1646108","asserted-by":"object"}]},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"article-number":"1582714"}}